STAT News reports that EchoNext, a new artificial intelligence tool cleared by the U.S. Food and Drug Administration (FDA), is being added to OpenEvidence. The tool is designed to help clinicians screen patients for structural heart diseases using an electrocardiogram (EKG). With this integration, doctors can run the AI analysis based on EKG data as part of their evaluation workflow, with the stated goal of making screening easier and more scalable.
The report frames the update as part of a broader expansion of health technology features within OpenEvidence. STAT also notes, in the same coverage segment, that other health tech activity is ongoing, including separate funding by another company (Cadence raising $100 million). However, the core details across the included sources focus on EchoNext’s FDA clearance, its intended use with EKGs, and its deployment within OpenEvidence to support detection of structural heart conditions.
The information presented is based on STAT’s summaries and emphasizes regulatory clearance and the planned clinical use case through OpenEvidence.
